Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug

Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methyle...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RSC advances 2019-06, Vol.9 (33), p.18844-18852
Hauptverfasser: Kowouvi, Koffi, Alies, Bruno, Gendrot, Mathieu, Gaubert, Alexandra, Vacher, Gaelle, Gaudin, Karen, Mosnier, Joel, Pradines, Bruno, Barthelemy, Philippe, Grislain, Luc, Millet, Pascal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested in vitro on sensitive or multidrug resistant strains of Plasmodium falciparum , was statistically similar to MB alone, with a slightly lower IC 50 . This nucleolipid-based approach to protect drugs against degradation represents a new alternative tool to be considered for malaria treatment. Nucleolipids protects methylene blue against reduction (induced by light and chemical reductants) and do not impair antimalarial activity.
ISSN:2046-2069
2046-2069
DOI:10.1039/c9ra02576f